119 related articles for article (PubMed ID: 37806058)
21. Exploration of Novel Inhibitors for Class I Histone Deacetylase Isoforms by QSAR Modeling and Molecular Dynamics Simulation Assays.
Noor Z; Afzal N; Rashid S
PLoS One; 2015; 10(10):e0139588. PubMed ID: 26431201
[TBL] [Abstract][Full Text] [Related]
22. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
[TBL] [Abstract][Full Text] [Related]
23. Histone Deacetylase 2 (HDAC2) Inhibitors Containing Boron.
Kavianpour P; Gemmell MCM; Kahlert JU; Rendina LM
Chembiochem; 2020 Oct; 21(19):2786-2791. PubMed ID: 32367603
[TBL] [Abstract][Full Text] [Related]
24. Computational identification of novel histone deacetylase inhibitors by docking based QSAR.
Nair SB; Teli MK; Pradeep H; Rajanikant GK
Comput Biol Med; 2012 Jun; 42(6):697-705. PubMed ID: 22521374
[TBL] [Abstract][Full Text] [Related]
25. Unveiling Arformoterol as a potent LSD1 inhibitor for breast cancer treatment: A comprehensive study integrating 3D-QSAR pharmacophore modeling, molecular docking, molecular dynamics simulations and in vitro assays.
Rezaei H; Zarezade V; Khodadadi I; Tavilani H; Tanzadehpanah H; Karimi J
Int J Biol Macromol; 2024 Feb; 258(Pt 2):129048. PubMed ID: 38159701
[TBL] [Abstract][Full Text] [Related]
26. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
Kim SL; La MT; Shin MW; Kim SW; Kim HK
Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis, and Biological Evaluation of 2-Anilino-4-Triazolpyrimidine Derivatives as CDK4/HDACs Inhibitors.
Wang S; Han S; Cheng W; Miao R; Li S; Tian X; Kan Q
Drug Des Devel Ther; 2022; 16():1083-1097. PubMed ID: 35431540
[TBL] [Abstract][Full Text] [Related]
28. An Improved Protocol for the Virtual Screening Discovery of Novel Histone Deacetylase Inhibitors.
Song Q; Liu T; Liu Y; Wang S; Fan C; Zheng L; Bao Y; Sun L; Yu C; Sun Y; Song Z; Wang G; Huang Y; Li Y
Chem Pharm Bull (Tokyo); 2019 Oct; 67(10):1076-1081. PubMed ID: 31406093
[TBL] [Abstract][Full Text] [Related]
29. Identification of potent histone deacetylase 2 (HDAC2) inhibitors through combined structure and ligand-based designs and molecular modelling approach.
Anand A; Ghosh P; Singh R; Gajanan Bajad N; Kumar A; Singh SK
J Biomol Struct Dyn; 2024 Jun; 42(9):4679-4698. PubMed ID: 37306006
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors.
Routholla G; Pulya S; Patel T; Abdul Amin S; Adhikari N; Biswas S; Jha T; Ghosh B
Bioorg Chem; 2021 Sep; 114():105050. PubMed ID: 34120025
[TBL] [Abstract][Full Text] [Related]
31. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Jang YG; Hwang KA; Choi KC
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Gediya P; Parikh PK; Vyas VK; Ghate MD
Eur J Med Chem; 2021 Apr; 216():113332. PubMed ID: 33714914
[TBL] [Abstract][Full Text] [Related]
33. Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and
Jin X; Wang Y; Chen J; Niu M; Yang Y; Zhang Q; Bao G
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2289355. PubMed ID: 38059332
[TBL] [Abstract][Full Text] [Related]
34. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
[TBL] [Abstract][Full Text] [Related]
35. Hydroxamic acid derivatives as selective HDAC3 inhibitors: computer-aided drug design strategies.
Patel P; Shrivastava SK; Sharma P; Kurmi BD; Shirbhate E; Rajak H
J Biomol Struct Dyn; 2024; 42(1):362-383. PubMed ID: 36995068
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.
Duan YC; Ma YC; Qin WP; Ding LN; Zheng YC; Zhu YL; Zhai XY; Yang J; Ma CY; Guan YY
Eur J Med Chem; 2017 Nov; 140():392-402. PubMed ID: 28987602
[TBL] [Abstract][Full Text] [Related]
37. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
[TBL] [Abstract][Full Text] [Related]
38. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
39. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.
Basant N; Lin X; Reid TE; Karla PK; Wang XS
Comb Chem High Throughput Screen; 2015; 18(7):693-700. PubMed ID: 26144283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]